MedTrace Logo

Statin Impact on Hepatic Decompensation

NCT05563389 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-04-03

No results posted yet for this study

Summary

The study aims to evaluate the impact of statin on hepatic decompensation.

Conditions

  • Quality of Life

Interventions

DRUG

Atorvastatin 20mg

active arm

DRUG

Placebo

placebo arm

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • khadija glal · assistant lecturer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-02-25
Completion
2023-02-25

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563389 on ClinicalTrials.gov